SMTL ID : 6p5m.5 (5 other biounits)

Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Anti-Tumor Agent

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.65 Å

Oligo State

homo-dimer

Ligands

1 x O1S: 6-(5-methyl-1H-pyrazol-4-yl)-2-[(pyrrolidin-1-yl)methyl]thieno[3,2-d]pyrimidin-4(3H)-one(Non-covalent)

O1S.1: 16 residues within 4Å: Chain A: I.86, V.94, A.107, K.109, E.128, V.141, M.157, E.158, Y.159, M.160, K.204, D.206, N.207, L.209, A.219, D.220 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:V.141, A:M.157, A:D.206 Hydrogen bonds: A:E.158, A:M.160, A:D.220, A:D.220 Salt bridges: A:D.220

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Kurasawa, O. et al., Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent. J.Med.Chem. (2020)

Release Date

2020-01-15

Peptides

Rho-associated protein kinase 2: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
D

Rho-associated protein kinase 2

Related Entries With Identical Sequence